Alnylam to Participate in Major Obesity Research Grant Awarded to Scientists at University of Texas (UT) Southwestern Medical Center

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced its participation in a $22 million Roadmap Grant from the National Institutes of Health (NIH) awarded to leading scientists at UT Southwestern for research on obesity.
Alnylam